跳至主要内容
临床试验/ITMCTR2000003983
ITMCTR2000003983招募中1 期

The efficacy of Qidongbufei Decoction in treating NSCLC postoperative symptoms: a randomized, double-blind, placebo-controlled pilot study

Guang'anmen Hospital, China Academy of Chinese Medical Sciences.0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • 1. Postoperative patients with NSCLC in stage I, confirmed by pathology or cytology;
  • 2. Enrolled within 2 weeks after surgery;
  • 3. The surgical mode is single hole thoracoscopic lobectomy
  • 4. Aged 18-75 years;
  • 5. ECOG 0-2 scores;
  • 6. The expected survival time equal or greater than 6 months;
  • 7. NEUT >1.5 x 10^9/L, PLT > 100 x 10^9/L, Hb > 9.0g/dl, TBIL normal or > 1.5 ULN; AST (SGOT)ALT (SGPT) < 2.5 ULN, CRE < 1.5 ULN.

排除标准

  • 1. Patients who received neoadjuvant chemotherapy before surgery;
  • 2. Patients who plan to receive other treatments such as radiotherapy, chemotherapy, targeted therapy, etc.within 1 month after surgery;
  • 3. Severe complications like pulmonary embolism, respiratory failure and myocardial infarction occurred during the perioperative period;
  • 4. In other clinical trials;
  • 5. Pregnant or lactating patients;
  • 6. Having a history of mental illness that is difficult to control;
  • 7. Allergic to study drugs;
  • 8. Cannot understand and refuse to sign informed consent;
  • 9. Cannot cooperate with the scale data collection.

研究者

相似试验